Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGEMNASDAQ:IMTXNASDAQ:LENZNASDAQ:VCKA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGEMCullinan Therapeutics$7.53-3.0%$8.14$6.85▼$21.01$457.95M-0.04519,791 shs304,274 shsIMTXImmatics$5.38-0.9%$5.25$3.30▼$13.09$660.02M0.83676,862 shs837,731 shsLENZLENZ Therapeutics$29.31-2.9%$28.68$16.54▼$38.93$849.45M0.42190,830 shs127,393 shsVCKAVickers Vantage Corp. I$10.07$8.03▼$11.17$118.72M0.0336,105 shs1,404 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGEMCullinan Therapeutics0.00%+1.17%-10.39%+2.51%-55.50%IMTXImmatics0.00%-3.21%-2.51%+20.40%-53.27%LENZLENZ Therapeutics0.00%+0.80%+3.04%+17.39%+74.55%VCKAVickers Vantage Corp. I0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGEMCullinan Therapeutics2.2099 of 5 stars3.51.00.00.02.71.70.6IMTXImmatics3.041 of 5 stars3.64.00.00.03.51.70.0LENZLENZ Therapeutics1.3311 of 5 stars3.60.00.00.02.20.80.0VCKAVickers Vantage Corp. IN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGEMCullinan Therapeutics 3.00Buy$30.00298.41% UpsideIMTXImmatics 3.20Buy$14.67172.61% UpsideLENZLENZ Therapeutics 3.17Buy$46.6058.99% UpsideVCKAVickers Vantage Corp. I 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VCKA, LENZ, IMTX, and CGEM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025CGEMCullinan TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$22.005/28/2025IMTXImmaticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.005/12/2025CGEMCullinan TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $24.005/8/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/16/2025CGEMCullinan TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $33.004/16/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/14/2025LENZLENZ TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$38.00 ➝ $51.004/1/2025IMTXImmaticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGEMCullinan TherapeuticsN/AN/AN/AN/A$10.14 per shareN/AIMTXImmatics$168.65M3.88$0.24 per share22.22$5.12 per share1.05LENZLENZ TherapeuticsN/AN/AN/AN/A$7.42 per shareN/AVCKAVickers Vantage Corp. IN/AN/AN/A374.61($0.91) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGEMCullinan Therapeutics-$167.38M-$2.91N/AN/AN/AN/A-29.47%-28.19%8/6/2025 (Estimated)IMTXImmatics$16.47M-$0.17N/AN/AN/A-14.73%-4.52%-3.34%8/12/2025 (Estimated)LENZLENZ Therapeutics-$49.77M-$1.77N/AN/AN/AN/A-23.74%-22.65%8/13/2025 (Estimated)VCKAVickers Vantage Corp. I$780KN/A0.00N/AN/AN/A-16.72%1.34%N/ALatest VCKA, LENZ, IMTX, and CGEM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025IMTXImmatics-$0.39-$0.35+$0.04-$0.35$14.92 million$20.12 million5/8/2025Q1 2025CGEMCullinan Therapeutics-$0.78-$0.74+$0.04-$0.74N/AN/A5/7/2025Q1 2025LENZLENZ Therapeutics-$0.55-$0.53+$0.02-$0.53N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGEMCullinan TherapeuticsN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/AVCKAVickers Vantage Corp. IN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGEMCullinan TherapeuticsN/A11.6211.62IMTXImmaticsN/A10.2810.28LENZLENZ TherapeuticsN/A23.0923.09VCKAVickers Vantage Corp. IN/A0.201.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGEMCullinan Therapeutics86.31%IMTXImmatics64.41%LENZLENZ Therapeutics54.32%VCKAVickers Vantage Corp. I84.46%Insider OwnershipCompanyInsider OwnershipCGEMCullinan Therapeutics6.07%IMTXImmaticsN/ALENZLENZ Therapeutics6.90%VCKAVickers Vantage Corp. I20.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGEMCullinan Therapeutics3059.01 million55.43 millionOptionableIMTXImmatics260121.55 millionN/AOptionableLENZLENZ Therapeutics11028.15 million26.20 millionN/AVCKAVickers Vantage Corp. IN/A13.18 million10.54 millionNot OptionableVCKA, LENZ, IMTX, and CGEM HeadlinesRecent News About These CompaniesMurder charges against teen's mother droppedAugust 25, 2024 | bbc.comBRealty Income Corp ONovember 1, 2023 | morningstar.comMClover Corp.September 8, 2023 | forbes.comVickers Vantage Corp. I WarrantJuly 8, 2023 | thestreet.comKDKGF - Klondike Gold Corp.June 26, 2023 | finance.yahoo.comSelwyn M. VickersMarch 18, 2023 | statnews.comSSarah Kellen Vickers: 5 Fast Facts You Need to KnowMarch 17, 2023 | heavy.comHMiddleby Corp. reports sale increaseFebruary 23, 2023 | dailyherald.comD8-K: Lifevantage CorpFebruary 18, 2023 | marketwatch.comVickers Vantage Corp I (VCKAU)February 12, 2023 | investing.comKCI arises: Concessions manager aims to create 'extraordinary experience' for travelersJanuary 29, 2023 | bizjournals.comVantage Point providing a taste of EuropeJanuary 15, 2023 | bangkokpost.comBAdopt a pet in need through Vickers Animal RescueJanuary 15, 2023 | wjhg.comWIs Vickers Vantage Corp I (SCLX) Stock a Good Investment?November 15, 2022 | aaii.comAThe Funded: Shares of Palo Alto's Scilex up 12% since it hit Wall Street in the Bay Area's 14th SPAC merger of 2022November 15, 2022 | finance.yahoo.comShares of newly public biotech Scilex climb 5% following SPAC mergerNovember 11, 2022 | seekingalpha.comVickers Vantage Corp. I Ordinary Shares (VCKA)August 24, 2022 | nasdaq.comScilex Holding Company, a Sorrento Company, Announces Exclusive Product Distribution Agreement ...August 18, 2022 | bakersfield.comBVickers Vantage Corp. IAugust 16, 2022 | wsj.comSorrento's Scilex repurchases $41.4M notes ahead of going public with SPAC Vickers VantageJune 3, 2022 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVCKA, LENZ, IMTX, and CGEM Company DescriptionsCullinan Therapeutics NASDAQ:CGEM$7.53 -0.23 (-2.96%) As of 04:00 PM EasternCullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Immatics NASDAQ:IMTX$5.38 -0.05 (-0.92%) As of 04:00 PM EasternImmatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.LENZ Therapeutics NASDAQ:LENZ$29.31 -0.87 (-2.88%) As of 04:00 PM EasternLENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Vickers Vantage Corp. I NASDAQ:VCKAAs of November 10, 2022, Vickers Vantage Corp. I was acquired by Scilex Holding Company, in a reverse merger transaction. Vickers Vantage Corp. I does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
